Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Carcinoma, Medullary 1Adenocarcinoma, Follicular 1

Interventions

Magnetic Resonance Spectroscopy 9Iodine-131 7Thyrotropin Alfa 5trametinib 3lenvatinib 3cabozantinib 3Sunitinib 3Specimen Handling 3Fluorodeoxyglucose F18 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3vandetanib 2dabrafenib 2X-Rays 2Trastuzumab 2Sorafenib 2Rosiglitazone 2Radiotherapy 2Interviews as Topic 2Gefitinib 2Everolimus 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1tremelimumab 1tipifarnib 1tanespimycin 1spartalizumab 1selpercatinib 1sargramostim 1romidepsin 1pembrolizumab 1pazopanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Follicular × tanespimycin × Endocrine × Clear all
NCT00118248 2017-02-15

Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Completed
41 enrolled 10 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡